BioAge Labs upgraded by Jefferies with a new price target
$BIOA
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded BioAge Labs from Hold to Buy and set a new price target of $62.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2026 | $36.00 | Buy | Roth Capital |
| 5/13/2026 | $40.00 | Buy | BTIG Research |
| 3/27/2026 | $50.00 | Buy | Needham |
| 2/25/2026 | $60.00 | Outperform | Oppenheimer |
| 2/18/2026 | $62.00 | Hold → Buy | Jefferies |
| 1/27/2026 | $73.00 | Overweight | Piper Sandler |
| 12/5/2025 | $12.00 | Underweight → Equal-Weight | Morgan Stanley |
| 10/22/2025 | $10.00 | Neutral → Buy | Citigroup |
8-K - BioAge Labs, Inc. (0001709941) (Filer)
SCHEDULE 13G/A - BioAge Labs, Inc. (0001709941) (Subject)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
Roth Capital initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $36.00
BTIG Research initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $40.00
Needham initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $50.00
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype. The data were presented during the session "Developing Topics Session #3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings" at the Al
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP); trial designed to support optimal dose selection for Phase 3 Trial builds on previously reported Phase 1 results in which BGE-102 achieved potential best-in-class hsCRP reductions and was well tolerated across all dose levels Topline data anticipated in the second half of 2026 EMERYVILLE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinic
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • Jefferies Global Healthcare Conference (New York, June 3–4, 2026): Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, are scheduled to participate in a fireside chat on Thursday, June 4 at 3:45–4:15 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. • Gol
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge" or the "Company"), a clinical-stage biopharm
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)